{
    "id": 4896,
    "name": "bile duct adenocarcinoma",
    "source": "DOID",
    "definition": "A bile duct carcinoma that derives_from epithelial cells of glandular origin. [url:http\\://en.wikipedia.org/wiki/Adenocarcinoma]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:4896",
    "evidence": [
        
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT01825603",
            "title": "ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4952,
                    "therapyName": "ADH-1 + Cisplatin + Gemcitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03267940",
            "title": "Open-Label Study of PEGPH20 With CIS and GEM; PEGPH20 With Atezolizumab, CIS and GEM; and Compared With CIS and GEM Alone in HA-high Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1467,
                    "therapyName": "Cisplatin + Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 6534,
                    "therapyName": "Atezolizumab + Cisplatin + Gemcitabine + PEGPH20",
                    "synonyms": null
                },
                {
                    "id": 6533,
                    "therapyName": "Cisplatin + Gemcitabine + PEGPH20",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03801915",
            "title": "Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5712,
                    "therapyName": "MVT-5873",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04042831",
            "title": "Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                }
            ]
        }
    ]
}